Equity Overview
Price & Market Data
Price: $7.07
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $26,034,780
Daily Volume: 0
Performance Metrics
1 Week: -6.23%
1 Month: -4.97%
3 Months: 6.00%
6 Months: -41.47%
1 Year: -65.58%
YTD: -34.83%
Company Details
Employees: 25
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.